$ENVB

$1.42 +$0.04 (2.9%) Close

$ENVB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 4.5M shares outstanding

Who owns ENVB?

By type of holder

Institutions 11.8% Insiders 14.0% Everyone else 74.1%

Concentration Top 10 holders own 20.5%

Tucker Joseph Edward 6.3% · Coveney Kevin Michael 4.0%

Institutional ownership

11.8%

+10.6 pts vs last qtr

Institutional holders

+13 vs last qtr

Net shares bought

+474.9K

by institutions in Q2 2026

New / sold out

14 / 1

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Sio Capital Management, LLC NEW +180.0K
Ikarian Capital, LLC NEW +100.0K

Biggest sellers in Q2 2026

Geode Capital Management, LLC −20.4K
UBS Group AG −3.4K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Enveric Biosciences Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+698.7%

+698.70% a year

Each share's claim on the business

−87.5%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $2.39M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years8% 1–3 years1% Under 1 year92%

Quarterly turnover

475.2%

of institutional shares changed hands

Top 10 managers, median time held

0 quarters

Super Investors

Investment managers reporting ENVB on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
SC Sio Capital Management, LLC	180.0K	4.02%	NEW	Q2 '26	0.0%
Shares held by quarter Peak holding180.0K (Q2'26) Change over 8 quarters+180.0K Share of the company4.020% Sio Capital Management, LLC's full portfolio →
IC Ikarian Capital, LLC	100.0K	2.23%	NEW	Q2 '26	0.0%
Shares held by quarter Peak holding100.0K (Q2'26) Change over 8 quarters+100.0K Share of the company2.230% Ikarian Capital, LLC's full portfolio →

Sio Capital Management, LLC

180.0K

% of company

4.02%

Change vs last qtr

NEW

Held since

Q2 '26

Ikarian Capital, LLC

100.0K

% of company

2.23%

Change vs last qtr

NEW

Held since

Q2 '26

23 more super investors behind a free account

See every manager holding Enveric Biosciences Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ENVB on Form N-PORT; together they hold 1.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
AP AdvisorShares Psychedelics ETF AdvisorShares Trust	$48.9K	35.4K	0.79%	0.11%	June 30, 2026
FE Fidelity Extended Market Index Fund Fidelity Concord Street Trust	$24.1K	17.6K	0.39%	0.00%	August 31, 2026

AdvisorShares Psychedelics ETF

AdvisorShares Trust

Position value

$48.9K

% of company

0.79%

% of the fund

0.11%

As of

June 30, 2026

Fidelity Extended Market Index Fund

Fidelity Concord Street Trust

Position value

$24.1K

% of company

0.39%

% of the fund

0.00%

As of

August 31, 2026

3 more funds behind a free account

See every fund holding Enveric Biosciences Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
TJ Tucker Joseph Edward Insider	280.9K	6.28%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company6.280% Tucker Joseph Edward's insider activity →
CK Coveney Kevin Michael Insider	180.7K	4.04%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company4.040% Coveney Kevin Michael's insider activity →

Tucker Joseph Edward

Insider

280.9K

% of company

6.28%

Change vs last qtr

—

Held since

—

Coveney Kevin Michael

Insider

180.7K

% of company

4.04%

Change vs last qtr

—

Held since

—

6 more holders behind a free account

See every insider and 5%+ holder of Enveric Biosciences Inc.

Comments